Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 39Lymphoma, Large B-Cell, Diffuse 38Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Lymphoma, Non-Hodgkin 29Recurrence 27Breast Neoplasms 27Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 20Hodgkin Disease 18Triple Negative Breast Neoplasms 17Melanoma 17Leukemia 17Ovarian Neoplasms 16Hematologic Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9

Interventions

Magnetic Resonance Spectroscopy 5Cyclophosphamide 5dinutuximab 3Topotecan 3Etoposide 3Doxorubicin 3Carboplatin 3Biopsy 3sargramostim 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Colony-Stimulating Factors 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2iberdomide 1gallium Ga 68 dotatate 1fludarabine 1Watchful Waiting 1Transurethral Resection of Bladder 1Temozolomide 1Razoxane 1Radiotherapy 1Proton Therapy 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Cyclophosphamide × 90 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
CNS

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡